{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T10:12:08Z","timestamp":1773828728595,"version":"3.50.1"},"reference-count":25,"publisher":"Oxford University Press (OUP)","issue":"12","license":[{"start":{"date-parts":[[2011,10,13]],"date-time":"2011-10-13T00:00:00Z","timestamp":1318464000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2011,12,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Osteoporosis Pseudoglioma (OPPG) is characterized by severe juvenile-onset osteoporosis and ocular abnormalities. It is caused by one of several inactivating mutations in LRP5, a gene importantly involved in bone formation. The objective of this study was to evaluate the efficacy of teriparatide in a young man with OPPG. The subject of this case report is a 19-year-old man with congenital blindness and low trauma fractures because of OPPG. A 2-year course of teriparatide, 20\u2009\u00b5g\/day, was initiated after a 6-year course of intravenous pamidronate infusions, the latter 3 years of which had minimal effects on bone mineral density (BMD). Measurements in serum were made of C-terminal telopeptide of type I collagen (CTX), N-terminal propeptide of type I collagen (P1NP), total and ionized calcium, phosphate, uric acid, complete blood count, and renal and liver function tests. Urinary calcium\/creatinine ratio was determined. BMD was measured by DXA yearly. BMD increased by 9.7% in lumbar spine and 10.2% in right femur hip. CTX rose early, peaking in month 3, followed by an increase in P1NP, peaking in month 9. Both indices returned to baseline by month 24. The increase in CTX followed by P1NP is an unusual time course when teriparatide is used to treat osteoporosis but may be typical of low bone turnover states. There were no adverse events. In a patient with OPPG, teriparatide markedly increased BMD in the lumbar spine and femur hip. \u00a9 2011 American Society for Bone and Mineral Research<\/jats:p>","DOI":"10.1002\/jbmr.530","type":"journal-article","created":{"date-parts":[[2011,10,13]],"date-time":"2011-10-13T13:32:28Z","timestamp":1318512748000},"page":"2823-2826","source":"Crossref","is-referenced-by-count":22,"title":["Teriparatide increases bone mineral density in a man with osteoporosis pseudoglioma"],"prefix":"10.1093","volume":"26","author":[{"given":"Henrique Pierotti","family":"Arantes","sequence":"first","affiliation":[{"name":"Bone and Mineral Unit, Division of Endocrinology, S\u00e3o Paulo Federal University, S\u00e3o Paulo, SP, Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elizabete Ribeiro","family":"Barros","sequence":"additional","affiliation":[{"name":"Bone and Mineral Unit, Division of Endocrinology, S\u00e3o Paulo Federal University, S\u00e3o Paulo, SP, Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ilda","family":"Kunii","sequence":"additional","affiliation":[{"name":"Bone and Mineral Unit, Division of Endocrinology, S\u00e3o Paulo Federal University, S\u00e3o Paulo, SP, Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John P","family":"Bilezikian","sequence":"additional","affiliation":[{"name":"College of Physicians and Surgeons, Columbia University, New York, NY, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marise","family":"Lazaretti-Castro","sequence":"additional","affiliation":[{"name":"Bone and Mineral Unit, Division of Endocrinology, S\u00e3o Paulo Federal University, S\u00e3o Paulo, SP, Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2011,10,13]]},"reference":[{"key":"2024020804162284100_bib1","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1086\/497706","article-title":"Clinical and molecular findings in osteoporosis pseudoglioma syndrome","volume":"77","author":"Ai","year":"2005","journal-title":"Am J Hum Genet."},{"issue":"4","key":"2024020804162284100_bib2","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/S0092-8674(01)00571-2","article-title":"LDL receptor-related protein 5 (LRP5) affects bone accrual and eye development","volume":"107","author":"Gong","year":"2001","journal-title":"Cell."},{"issue":"6","key":"2024020804162284100_bib3","first-page":"419","article-title":"Decreased bone density in carriers and patients of an Israeli family with the osteoporosis-pseudoglioma syndrome","volume":"5","author":"Lev","year":"2003","journal-title":"Isr Med Assoc J."},{"issue":"3","key":"2024020804162284100_bib4","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1016\/j.bone.2008.04.020","article-title":"Osteoporosis pseudoglioma syndrome: description of 9 new cases and beneficial response to bisphosphonates","volume":"43","author":"Streeten","year":"2008","journal-title":"Bone."},{"issue":"5","key":"2024020804162284100_bib5","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/j.cell.2008.09.059","article-title":"Lrp5 controls bone formation by inhibiting serotonin synthesis in the duodenum","volume":"135","author":"Yadav","year":"2008","journal-title":"Cell."},{"issue":"8","key":"2024020804162284100_bib6","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1515\/JPEM.2008.21.8.811","article-title":"Three years follow-up of pamidronate therapy in two brothers with osteoporosis-pseudoglioma syndrome (OPPG) carrying an LRP5 mutation","volume":"21","author":"Barros","year":"2008","journal-title":"J Pediatr Endocrinol Metab."},{"issue":"33","key":"2024020804162284100_bib7","doi-asserted-by":"crossref","first-page":"23698","DOI":"10.1074\/jbc.M601000200","article-title":"The Wnt Co-receptor LRP5 is essential for skeletal mechanotransduction but not for the anabolic bone response to parathyroid hormone treatment","volume":"281","author":"Sawakami","year":"2006","journal-title":"J Biol Chem."},{"issue":"7","key":"2024020804162284100_bib8","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1007\/s00198-007-0360-x","article-title":"A novel mutation in the LRP5 gene is associated with osteoporosis-pseudoglioma syndrome","volume":"18","author":"Barros","year":"2007","journal-title":"Osteoporos Int."},{"issue":"19","key":"2024020804162284100_bib9","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1056\/NEJM200105103441904","article-title":"Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis","volume":"344","author":"Neer","year":"2001","journal-title":"N Engl J Med."},{"issue":"34","key":"2024020804162284100_bib10","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1080\/01926230490462138","article-title":"Bone neoplasms in F344 rats given teriparatide [rhPTH(1-34)] are dependent on duration of treatment and dose","volume":"32","author":"Vahle","year":"2004","journal-title":"Toxicol Pathol."},{"issue":"20","key":"2024020804162284100_bib11","doi-asserted-by":"crossref","first-page":"2028","DOI":"10.1056\/NEJMoa071408","article-title":"Teriparatide or alendronate in glucocorticoid-induced osteoporosis","volume":"357","author":"Saag","year":"2007","journal-title":"N Engl J Med."},{"issue":"4","key":"2024020804162284100_bib12","first-page":"1214","article-title":"Increases in bone mineral density after discontinuation of daily human parathyroid hormone and gonadotropin-releasing hormone analog administration in women with endometriosis","volume":"84","author":"Finkelstein","year":"1999","journal-title":"J Clin Endocrinol Metab."},{"key":"2024020804162284100_bib13","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1007\/978-1-59745-459-9_22","volume-title":"Osteoporosis\u2014Pathophysiology and Clinical Management","author":"Bilezikian","year":"2010","edition":"2nd edition"},{"issue":"4","key":"2024020804162284100_bib14","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1359\/jbmr.070104","article-title":"Effects of a one-month treatment with PTH(1-34) on bone formation on cancellous, endocortical, and periosteal surfaces of the human ilium","volume":"22","author":"Lindsay","year":"2007","journal-title":"J Bone Miner Res."},{"issue":"9","key":"2024020804162284100_bib15","doi-asserted-by":"crossref","first-page":"4214","DOI":"10.1210\/jc.2002-021736","article-title":"Long-term treatment of hypoparathyroidism: a randomized controlled study comparing parathyroid hormone-(1-34) versus calcitriol and calcium","volume":"88","author":"Winer","year":"2003","journal-title":"J Clin Endocrinol Metab."},{"issue":"11","key":"2024020804162284100_bib16","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.1007\/s00198-009-1149-x","article-title":"Therapy of hypoparathyroidism with intact parathyroid hormone","volume":"21","author":"Rubin","year":"2010","journal-title":"Osteoporos Int."},{"key":"2024020804162284100_bib17","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1359\/jbmr.040117","article-title":"Differential effects of teriparatide on BMD after treatment with raloxifene or alendronate","volume":"19","author":"Ettinger","year":"2004","journal-title":"J Bone Miner Res."},{"key":"2024020804162284100_bib18","doi-asserted-by":"crossref","first-page":"3785","DOI":"10.1210\/jc.2008-0353","article-title":"Early responsiveness of women with osteoporosis to teriparatide after therapy with alendronate or risedronate","volume":"93","author":"Miller","year":"2008","journal-title":"J Clin Endocrinol Metab."},{"issue":"1","key":"2024020804162284100_bib19","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1359\/jbmr.2001.16.1.104","article-title":"Primary prevention of glucocorticoid-induced osteoporosis with intravenous pamidronate and calcium: a prospective controlled 1-year study comparing a single infusion, an infusion given once every 3 months, and calcium alone","volume":"16","author":"Boutsen","year":"2001","journal-title":"J Bone Miner Res."},{"issue":"13","key":"2024020804162284100_bib20","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1056\/NEJMoa010845","article-title":"Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer","volume":"345","author":"Smith","year":"2001","journal-title":"N Engl J Med."},{"issue":"8","key":"2024020804162284100_bib21","doi-asserted-by":"crossref","first-page":"2915","DOI":"10.1210\/jc.2008-2630","article-title":"Effects of teriparatide treatment and discontinuation in postmenopausal women and eugonadal men with osteoporosis","volume":"94","author":"Leder","year":"2009","journal-title":"J Clin Endocrinol Metab."},{"issue":"9","key":"2024020804162284100_bib22","first-page":"3069","article-title":"Parathyroid hormone as a therapy for idiopathic osteoporosis in men: effects on bone mineral density and bone markers","volume":"85","author":"Kurland","year":"2000","journal-title":"J Clin Endocrinol Metab."},{"issue":"6","key":"2024020804162284100_bib23","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1359\/jbmr.081250","article-title":"Retreatment with teriparatide one year after the first teriparatide course in patients on continued long-term alendronate","volume":"24","author":"Cosman","year":"2009","journal-title":"J Bone Miner Res."},{"issue":"2","key":"2024020804162284100_bib24","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.bone.2005.03.018","article-title":"SOST is a target gene for PTH in bone","volume":"37","author":"Keller","year":"2005","journal-title":"Bone."},{"issue":"5","key":"2024020804162284100_bib25","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1007\/s00223-010-9350-7","article-title":"Genetic analysis of Lrp5 function in osteoblast progenitors","volume":"86","author":"Yadav","year":"2010","journal-title":"Calcif Tissue Int."}],"container-title":["Journal of Bone and Mineral Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fjbmr.530","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/jbmr\/article-pdf\/26\/12\/2823\/56557624\/530_ftp.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jbmr\/article-pdf\/26\/12\/2823\/56557624\/530_ftp.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,13]],"date-time":"2024-03-13T14:48:16Z","timestamp":1710341296000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jbmr\/article\/26\/12\/2823-2826\/7597898"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,10,13]]},"references-count":25,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2011,10,13]]},"published-print":{"date-parts":[[2011,12,1]]}},"URL":"https:\/\/doi.org\/10.1002\/jbmr.530","relation":{},"ISSN":["0884-0431","1523-4681"],"issn-type":[{"value":"0884-0431","type":"print"},{"value":"1523-4681","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2011,12,1]]},"published":{"date-parts":[[2011,10,13]]}}}